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Abstract
Background: For children at high risk of chronic suppurative otitis media (CSOM), strategies to
prevent acute otitis media with perforation (AOMwiP) may reduce progression to CSOM.
Methods: In a double blind study in northern Australia, 103 Aboriginal infants with first detection
of OME were randomised to receive either amoxicillin (50 mg/kg/d BD) or placebo for 24 weeks,
or until bilateral aerated middle ears were diagnosed at two successive monthly examinations
(success). Standardised clinical assessments and international standards for microbiology were
used.
Results: Five of 52 infants in the amoxicillin group and none of 51 infants in the placebo group
achieved success at the end of therapy (Risk Difference = 9.6% [95% confidence interval 1.6,17.6]).
Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy
(27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14%
[-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during
therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017). During therapy, the proportion
of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci was not
significantly different between the amoxicillin group (34%) and the placebo group (40%). Beta-
lactamase positive non-capsular H. influenzae (NCHi) were uncommon during therapy but more
frequent in the amoxicillin group (10%) than placebo (5%).
Conclusion: Aboriginal infants receiving continuous amoxicillin had more normal ears, fewer
perforations, and less pneumococcal carriage. There was no statistically significant increase in
resistant pneumococci or NCHi in amoxicillin children compared to placebo children who received
regular paediatric care and antibiotic treatment for symptomatic illnesses.
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Otitis media (OM) is an important health problem in
young children. In most settings the pain or fever of acute
OM (AOM) is of principal concern. However, in disad-
vantaged and Indigenous populations, where sympto-
matic AOM is less often reported, AOM with tympanic
membrane perforation (AOMwiP) and progression to
chronic suppurative OM (CSOM) can lead to hearing
impairment and educational disadvantage. CSOM is esti-
mated to currently affect between 65 and 330 million peo-
ple, 60% of whom have a significant hearing loss [1] This
global burden mainly affects South East Asia, Western
Pacific, Africa and ethnic minorities. A 2001 cross-sec-
tional survey of Aboriginal children aged 6 months to 2.5
years living in 29 remote Aboriginal communities in the
Northern Territory of Australia, showed perforation rates
varying from 0% to 60% (mean rate 24%) between com-
munities [2]. In longitudinal studies of Aboriginal chil-
dren, OM has been shown to commence within weeks of
birth, shortly after nasopharyngeal colonisation with
Streptococcus pneumoniae, non-capsular Haemophilus influ-
enzae (NCHi) and Moraxella catarrhalis.[3] This link
between bacterial colonisation and early onset of persist-
ent OM suggested to us that long-term antibiotic therapy
could be of benefit for Aboriginal infants and others in
high-risk populations. The impact of antibiotics has been
unclear in populations where rates of CSOM exceed 4%,
although systematic reviews demonstrate that antibiotics
do prevent some episodes of AOM in more affluent pop-
ulations, [4,5] and are particularly beneficial for children
with more severe OM [6].
Methods
Aims
To compare the effects of long-term antibiotics and pla-
cebo on otitis media with effusion (OME) and nasopha-
ryngeal carriage of antibiotic-resistant OM bacterial
pathogens in a high-risk population.
Participants and Setting
The study was conducted in three Aboriginal communi-
ties located 70 Km from Darwin, in tropical northern Aus-
tralia. During the study period breastfeeding was
universal, parental smoking extremely common, and for-
mal childcare was unavailable. Data collection com-
menced in 1996 and was completed in 2001, when
pneumococcal conjugate vaccine was about to be licensed
in Australia.
Eligibility and exclusion criteria
Enrolled infants were Aboriginal, less than 12 months of
age and resident in a study community. Infants were
enrolled as soon as possible after birth, examined every
two weeks, and those with unilateral or bilateral otitis
media with effusion (OME) were eligible for randomiza-
tion. Infants were excluded on the basis of prematurity
(<34 weeks), chronic infection requiring prophylactic
antibiotic therapy, craniofacial abnormalities or immune
deficiency syndromes.
Ethical and Funding Issues
The study was approved by the Top End Human Research
Ethics Committee and Aboriginal Sub-Committee, and
the Tiwi Health Board. Funding was provided by the
National Health and Medical Research Council, which
had no involvement in study design, management, or
reporting of results.
Consent procedures
Written informed consent was sought before enrolment
and also before randomization; families were given at
least 2 weeks to consider consent. Initially, consent for
microbiological assessments prior to randomisation was
not requested.
Randomised Intervention
Randomized participants received either amoxicillin (50
mg/kg/day bid) or placebo equivalent volume for 24
weeks or until bilateral normal middle ear status was
detected at two consecutive monthly examinations (suc-
cess). Block randomisation was stratified by age. Alloca-
tion was concealed from children, family, investigators,
and those providing routine clinical care. Blinding was
achieved by using a placebo similar in packaging, colour,
consistency and smell to amoxicillin suspension. Intercur-
rent illnesses were managed according to local commu-
nity treatment guidelines [7].
Further details of randomisation [see Additional File 1].
Diagnosis and Outcome assessments
Eligibility and scheduling
Baseline characteristics and pre-enrolment ear disease
were assessed from clinical records. Infants were exam-
ined fortnightly from enrolment to randomization, and
monthly over the 24 week intervention period or until
success was documented.
Assessments
At each study visit a paediatrician or pediatric nurse
trained by an Australian expert used video pneumatic
otoscopy and tympanometry (Grason Stadler GSI 38) to
assess ear status. Clinic notes were reviewed to assess
inter-current illness and side effects. Nasopharyngeal
swabs were collected at baseline and at each post-ran-
domisation visit, and processed as previously reported to
detect pneumococci, Haemophilus influenzae and Moraxella
catarrhalis [8-10].Page 2 of 9
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Diagnostic criteria were as previously reported [11]. Table
1 gives definitions and the severity scale used to assign the
worse (highest score) ear diagnosis at each examination.
In this study, ear examinations that demonstrated type B
tympanogram, reduced mobility on pneumatic otoscopy
and a marked or moderately bulging TM were categorised
as AOM without perforation (AOMwoP) even if the child
was asymptomatic.
Success
The primary outcome ('success'), was detection of bilat-
eral aerated middle ears (confirmed with tympanometry)
at two consecutive monthly visits.
Statistical power and methods
We aimed to achieve a sample size of 118 that would pro-
vide 80% power to detect a 20% increase in success rate
(5% to 25%). This would also give 88% power to detect a
30% reduction in perforation at the end of therapy (60%
to 30%). Interim analysis and stopping rule was intended
to be applied if the success rate in the active arm was 40%.
Data were analysed according to a pre-determined plan.
We used the outcome in the worse ear (the ear with the
highest severity score) to avoid dependence between ears.
Estimates of treatment effect are given as the difference
between amoxicillin and placebo groups in the prevalence
of each outcome at the end of therapy, as a difference in
the proportion of examinations during therapy (risk dif-
ference and unadjusted 95% confidence interval) or as a
adjusted risk ratio and 95% confidence interval (adjusted
for repeat child examinations using generalised linear
models – Poisson). For children who failed to complete
therapy, the last available assessment was used. Two sided
significance tests were used throughout. All calculations
used Stata version 9 [12].
Results
Participants [see Additional File 1]
From 188 births in the study period, family consent was
obtained to enrol 126 infants. 103 were randomised (Fig-
ure 1). Details of non-randomised infants and of those
who discontinued amoxicillin (n = 2) or placebo (n = 7).
Pre-randomisation details for randomised children (Table 
2)
In the period from birth to randomisation, diagnoses of
OM or respiratory illnesses other than OM, and antibiotic
use (oral or IM) had been documented by clinic staff for
more than half the children in each group (data not
shown). All children were less than 12 months of age at
enrolment. There were 321 examinations by study staff
between enrolment and randomisation; bilateral normal
ears were diagnosed in 12% of examinations, OME in
about 50%, AOM in 26%, and perforations in less than
10%.
52 infants were allocated to amoxicillin and 51 to pla-
cebo, and the groups were similar for mean age of moth-
ers, mean infant gestational age, proportion male,
number of study visits before randomisation, age at ran-
domisation, and distribution of ear-states prior to ran-
domisation. Mean birth weight was significantly greater
for placebo infants (p = 0.0013).
Ear states at randomisation
At randomisation 50 (96%) of amoxicillin infants and 49
(96%) of placebo infants had OME as the worst ear diag-
nosis; 3 infants had resolving AOM and started the inter-
vention study after an additional week of antibiotic
treatment; one infant (placebo) had unilateral dry perfo-
ration.
Table 1: Diagnostic criteria and severity scale for worse ear
Diagnosis Definition Severity scale for worse ear.
Normal Absence of middle ear inflammation or infection, normal 
mobility on pneumatic otoscopy, and type A, C1 or C2 
tympanogram.
0
Otitis media with effusion (OME) Fluid behind an intact tympanic membrane (TM), reduced 
mobility on pneumatic otoscopy or type B tympanogram, 
with or without mild bulging, and in the absence of signs 
or symptoms of acute infection.
1
Acute Otitis Media without perforation (AOMwoP) Fluid behind an intact TM, reduced mobility on pneumatic 
otoscopy or type B tympanogram, with moderate or 
marked bulging, with or without symptoms of acute 
infection and without signs of recent perforation.
2
AOM with perforation (AOMwiP) Discharge through a perforated TM for less than 6 weeks. 3
Chronic suppurative otitis media (CSOM) Discharge through a perforated TM for more than 6 
weeks despite appropriate treatment for AOMwiP.
4Page 3 of 9
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File 2]
On the day of randomisation, carriage of each respiratory
bacterial pathogen was high in both groups (between
73% and 81%). All three OM bacterial pathogens were
carried by half of the children in each group (54% and
53% respectively); penicillin non-susceptible (MIC> 0.1
μg.ml) pneumococci were carried by 27% and 37% in
amoxicillin and placebo groups, respectively. Beta-lacta-
mase producing H. influenzae were detected in 6% and 2%
of children respectively. None of these differences reached
statistical significance.
Outcomes at the end of therapy (Table 3)
No infant was withdrawn as a result of direct adverse reac-
tion due to medication. The mean duration of therapy was
5.7 months for amoxicillin infants and 5.2 months for
placebo infants. Mean ages at the end of therapy were 11.5
and 10.2 months.
There were 5 successes (bilateral aerated middle ears at
two successive monthly examinations) in the amoxicillin
group and none in the placebo group (Risk Difference =
+9.6% [95% Confidence Interval 1.6, 17.6]). Six infants in
the amoxicillin group had bilateral normal ears at the end
of therapy compared to no infant in the placebo group
(RD = +12% [3,20]). Most children had OME (54% and
51%, respectively); AOMwoP was diagnosed in 23% and
The Consort E-FlowchartFigure 1
The Consort E-Flowchart. Participant Flow in the COMIT1 Trial.
       Assessed for eligibility  (n= 126) 
Excluded  (n= 23) 
Not meeting inclusion 
criteria (7 CSOM, 1 CSLD, 1 
PUJ obstruction, 2 premature, 1 
>365 days)
(n= 12) 
 Refused randomization 
(n= 11)
Analyzed   (n= 52) 
Mean 5.5 examinations per child 
Mean 5.7 months therapy 
283 ear examinations 
24.4 child years 
Excluded from analysis  (n=  0)
Lost to follow-up  (n= 0) 
Discontinued amoxicillin 
      (n=  2) 
1 CSOM 
1 withdrawn by parent 
Allocated to amoxicillin 
(n= 52) 
Received allocated amoxicillin 
(n=  52) 
Lost to follow-up  (n= 2) 
No longer living in community 
Discontinued placebo 
      (n=  5) 
2 CSOM 
3 withdrawn by parent 
Allocated to placebo 
(n=  51) 
Received allocated placebo 
(n=  51) 
Analyzed   (n= 51) 
Mean 5.1 examinations per child 
Mean 5.2 months therapy 
253 ear examinations 
22.2 child years 
Excluded from analysis  (n=  0)
Allocation 
Analysis 
Follow-Up 
Enrolment
Randomized (n=103) Page 4 of 9
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amoxicillin group (12%) compared with placebo (27%).
Ear Assessments during therapy [see Additional Files 3 and 
4]
Bilaterally normal ears were seen at least once in 11 (21%)
amoxicillin infants and 5 (10%) placebo infants. More
children in the amoxicillin group had at least one diagno-
sis of OME and more had AOMwoP. Fewer amoxicillin
children had AOMwiP detected (25% and 33%, respec-
tively), and recurrent AOMwiP was identified in signifi-
cantly fewer amoxicillin children (4%) and than placebo
children (18%) (RD = -14% [-25, -2]).
Results were similar when expressed as a proportion of
examinations for each group. Bilateral normal ears were
detected in 6% and 2% of visits in amoxicillin and pla-
cebo infants, respectively (adjusted risk ratio = 2.7 [0.78,
9.13] p = 0.116). OME was the worst ear diagnosis at
about half the visits in each group, AOMwoP was detected
in about one quarter of visits. AOMwiP was less often
diagnosed in children receiving amoxicillin (8%) than
placebo (19%) (adjusted risk ratio = 0.36 [0.16, 0.84] p =
0.017). For combined diagnostic categories of any suppu-
rative OM, any perforation, and any active perforation,
significant differences in perforation were found. Antibi-
otic prescribing for a clinical indication was less often
required at examinations of amoxicillin children (55%)
then placebo children (68%) (adjusted risk ratio = 0.67
[0.36, 1.22] p = 0.190). Tables S2a and S2b give more
detail of ear status over the course of the trial [see Addi-
tional files 3 and 4].
Nasopharyngeal outcomes at the end of therapy (Table 2)
At the end of therapy, carriage of OM pathogens, and car-
riage of penicillin non-susceptible S. pneumoniae (34%
in amoxicillin group and 40% in placebo group) was not
significantly different between groups.
Nasopharyngeal outcomes during therapy [see Additional 
Files 3 and 4]
Over the course of the RCT, fewer amoxicillin swabs
(59%) than placebo swabs (78%) were positive for pneu-
mococcus (adjusted risk ratio = 0.77 [0.67, 0.88] p =
0.000). Recovery of NCHi was ~70% in each group. There
were non-significant differences in 7-valent pneumococ-
cal conjugate vaccine serotypes (42% versus 48% in
amoxicillin and placebo swabs, respectively, data not
shown) and M. catarrhalis (85% versus 90%). Fewer
amoxicillin swabs cultured all 3 pathogens simultane-
ously (46% versus 58%), but this was not statistically sig-
nificant (adjusted risk ratio = 0.64 [0.34, 1.23] p = 0.183).
During therapy, children in the amoxicillin group also
carried fewer penicillin non-susceptible pneumococci
(34% versus 40% in amoxicillin and placebo, respec-
tively), and fewer macrolide non-susceptible (16% versus
20%, data not shown) and multi-drug resistant (15% ver-
sus 20%, data not shown) pneumococci. Beta-lactamase
Table 2: Baseline characteristics and ear assessments between enrolment and randomisation (including day of enrolment and day of 
randomisation)
Amoxicillin Placebo
N = 52 N = 51
Mean age (years) of mothers 24.5 (N = 52) 23.3 (N = 50)
Mean gestation (weeks) 38.3 (N = 43) 38.5 (N = 46)
Mean birth weight (gm) 2812 (N = 51) 3155 (N = 50)
Male 24 (46%) 30 (59%)
Enrolment to randomisation (inclusive)
Mean age (mo) at enrolment 4.2 3.2
Mean duration to randomisation (months) 1.6 1.8
Number of study visits 155 166
Mean visits per child 2.5 2.6
Number (%) of examinations with the following worst ear status(enrolment to randomisation, 
inclusive)
N = 155 N = 166
Normal 18 (12%) 19 (11%)
Otitis media with effusion (OME) 83 (54%) 82 (49%)
Acute Otitis Media (AOM) without perforation (AOMwoP) 41 (26%) 44 (26%)
AOM with perforation (AOMwiP) 6 (4%) 10 (6%)
Dry perforation 1 1
Chronic Suppurative Otitis Media (CSOM) 0 2
Any suppurative OM† 47 (30%) 56 (34%)
Any perforation‡ 7 (5%) 13 (8%)
AOMwoP, AOMwiP or CSOM;
AOMwiP, dry perforation or CSOMPage 5 of 9
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(10%) than placebo (5%) swabs; these latter differences
did not reach statistical significance. Tables S2b and S3b
give more detail of carriage status over the course of the
trial [see Additional Files 3 and 4].
Discussion
We have studied OM in Aboriginal communities where
almost all children have persistent middle ear disease
from an early age [3]; nevertheless, our results could also
be relevant for other high-risk groups. The primary out-
come from our double-blind RCT is that amoxicillin sig-
nificantly increased the proportion of children achieving
normal middle ears (bilaterally aerated) at consecutive
monthly examinations. Amoxicillin also reduced the pro-
portion of children with any perforation. The proportion
with any suppurative OM was also less in the amoxicillin
group at the end of therapy, but not significantly so (Table
2). The proportion of children on amoxicillin experienc-
ing at least two episodes of AOMwiP during therapy was
less than for placebo children (4% versus 18%, respec-
tively). There was no difference between placebo and
amoxicillin in the proportion of children with OME
(~52% in each group) or AOMwoP (~22%) at the end of
therapy. Risk differences during therapy (supplementary
material) were consistent with the end of therapy find-
ings. Pneumococcal non-susceptibility was similar in
amoxicillin and placebo groups, however a greater pro-
portion of children in the amoxicillin group were colo-
nised by beta-lactamase producing H. influenzae at both
baseline and at end of therapy.
Our findings can be understood in terms of the natural
history of OM in high-risk populations. In Aboriginal
children, AOM is usually asymptomatic with parents una-
ware that their child is unwell. In community-based
screening, [13] some 20% to 30% of Aboriginal children
have bulging eardrums. Only a minority have the typical
symptoms (sudden onset of middle ear effusion with pain
or fever) which define AOM in low-risk populations [14].
To explain our findings in this high-risk population, we
suggest that in placebo recipients, asymptomatic middle
ear infection often progresses to AOM with perforation,
whereas continuous amoxicillin helps to prevent that pro-
Table 3: Ear assessments and nasopharyngeal carriage at the end of therapy
Amoxicillin Placebo
n = 52 n = 51
Mean duration of therapy (months) 5.7 5.2
Mean age (months) at the end of therapy 11.5 10.2
Number of children (%) with the following worst ear status at the end of therapy
Amoxicillin Placebo Risk Difference
n = 52 n = 51 [95% CI]
Success (bilateral normal ears at 2 successive monthly visits) 5 (9.6%) 0 +9.6% [1.6, 17.6]
Normal 6 (12%) 0 +12% [3, 20]
OME 28 (54%) 26 (51%) +3% [-16, 22]
AOM without perforation 12 (23%) 11 (22%) +1.5% [-15, 18]
AOM with perforation 5 (10%) 11 (22%) -12% [-26, 2]
Dry perforation 0 1 (2%) -2% [-6, 2]
CSOM 1 (2%) 2 (4%) -2% [-9, 5]
Any suppurative OM† 18 (35%) 24 (47%) -12% [-31, 6]
Any perforation‡ 6 (12%) 14 (27%) -16% [-31, -1]
Any active perforation§ 6 (12%) 13 (26%) -14% [-29, 1]
Bilateral AOM without perforation 4 (8%) 7 (13%) +5% [-6, 17]
Bilateral any perforation‡ 1 (2%) 7 (14%) -12% [-22, -2]
Number of children (%) with nasopharyngeal carriage of the following OM pathogens¥ 
at end of therapy
Amoxicillin Placebo Risk Difference
n = 50 n = 47 [95% CI]
Streptococcus pneumoniae 29 (58%) 33 (70%) -12% [-31, 7]
non-capsular Haemophilus influenzae 36 (72%) 29 (62%) +10% [-8, 29]
Moraxella catarrhalis 44 (88%) 43 (91%) -3% [-16,9]
All Spn, NCHi and M.cat 23 (46%) 21 (45%) 1% [-19, 21]
Penicillin non-susceptible Spn‡ 17 (34%) 19 (40%) -6% [-26, 13]
Penicillin resistant Spn†† 1 (2%) 2 (4%) -2.3% [-9, 5]
NCHi beta-lactamase positive 6 (12%) 1 (2%) +10% [-0.03, 20]
AOM, AOMwiP or CSOM; ‡ AOMwiP, dry perforation or CSOM; §AOMwiP or CSOM; ¥ Spn Streptococcus pneumoniae. NCHi non-capsular 
Haemophilus influenzae. Mcat Moraxella catarrhalis. ‡Penicillin intermediate or resistant Spn (MIC > = 0.1 μg/ml) ††Penicillin resistant Spn (MIC > 1.0 
μg/ml)Page 6 of 9
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short-term antibiotics for asymptomatic AOM which indi-
cated that the majority of children still satisfy the criteria
for AOM despite treatment for 7 to 14 days. [11] The
present study suggests that therapy can be more successful
if it is maintained long-term. We believe that this can be
explained by the association of bacterial load with
increased severity of OM [15]. It may be that continuous
antibiotics maintain bacterial load below a critical thresh-
old for more severe disease.
Our trial supports the notion that asymptomatic bulging
of the tympanic membrane is an important predictor of
AOM and perforation [16]; this has not been emphasised
in the AAP and AAFP guideline [14]. Furthermore, the
implications of withholding antibiotic therapy in children
with bulging eardrums have not previously been evalu-
ated in high quality studies. Guidelines for management
of AOM in Indigenous children define AOM as middle ear
effusion with either bulging of the tympanic membrane,
recent discharge, ear pain, or redness [17]. There is no
option to withhold antibiotics in an Aboriginal child with
AOM; for children in whom AOM is associated with per-
foration, longer courses of antibiotics are recommended.
Our RCT supports that recommendation.
A recent meta-analysis of individual patient data from
studies in low-risk populations identified subgroups most
likely to benefit from antibiotic therapy [6]. In children
younger than 2 years of age with bilateral acute otitis
media, 55% of controls and 30% on antibiotics still had
pain, fever, or both at 3–7 days, with a rate difference
between these groups of -25% (95% CI -36% to -14%),
resulting in a number-needed-to-treat (NNT) of four chil-
dren. In children with otorrhoea the rate difference and
NNT, respectively, were -36% (-53% to -19%) and three,
whereas in children without otorrhoea the equivalent val-
ues were -14% (-23% to -5%) and eight. From our results
in Aboriginal children (Table 2), the NNT would be about
ten for normalisation of ears, about six for prevention of
perforation, and about four for either beneficial outcome.
If compliance could be guaranteed in Aboriginal children,
each NNT would likely be reduced.
What are the microbiological implications of long-term
amoxicillin? Our study shows a significant reduction in
pneumococcal carriage during amoxicillin therapy.
Despite the positive results from our RCT it is unclear
whether withholding antibiotics in an asymptomatic
child at risk of perforation will result in a clinical deterio-
ration that outweighs the theoretical risk of increasing
antibiotic resistance should the child be treated. It is reas-
suring that in our RCT there was no increase in the car-
riage of penicillin-resistant pneumococci as a result of
treatment, nor any difference in antibiotics prescribed for
intercurrent illnesses between amoxicillin and placebo
children. Indeed there was a tendency for fewer children in
the amoxicillin group to be colonised by penicillin-resist-
ant pneumococci. On the other hand, although beta-
lactamase producing H. influenzae were uncommon in
both groups, they were detected more frequently in chil-
dren receiving amoxicillin; however, as this non-signifi-
cant trend was also present before the start of trial therapy,
it could be a chance finding.
Empirical studies of resistance are not available from
other randomised controlled trials of long term antibiot-
ics for otitis media [18]. The study of perforation in Alaska
natives [19], which also found that long-term antibiotics
were beneficial, did not report on antibiotic resistance. We
note that by 1997, 25% of Australian clinical isolates were
penicillin non-susceptible, and high levels of penicillin
resistance were reported from Aboriginal communities
from the mid 1980s [20].
We have previously shown that OM is more advanced
when multiple pathogens colonise the nasopharynx
simultaneously and at high density [15] We suggest that
the effect of long-term amoxicillin is to reduce the density
and multiplicity of bacterial carriage by reducing the rate
of acquisition of new strains and/or the rate of prolifera-
tion of those already acquired. In the Finnish OM study
[21] 28% of new pneumococcal acquisitions were associ-
ated with pneumococcal AOM, compared with only 11%
for established carriage.
We believe that our study of long-term antibiotic use is
very relevant for Aboriginal and other populations at high
risk of tympanic membrane perforation. Unfortunately
conjugate pneumococcal vaccine has not significantly
reduced ear disease in Australian Aboriginal children. A
recent pediatric outreach program in Far North Queens-
land confirms that CSOM is the most prevalent health
problem in Aboriginal children [22]. The poor school
achievement of Aboriginal children, already disadvan-
taged by poverty, has been partially attributed to the
chronic hearing loss [23].
Our study shows that Aboriginal infants with OME receiv-
ing continuous amoxicillin had fewer perforations, more
normal ears, less pneumococcal carriage and fewer resist-
ant pneumococci than children who received regular pae-
diatric care and antibiotic treatment for acute illnesses but
without continuous amoxicillin. The option to use long-
term antibiotics would be less relevant for western popu-
lations where the outcome of untreated OM is less severe,
and the balance of benefit and risk is less influenced by
the risk of a severe clinical outcome, and more influenced
by the potential for increased antibiotic resistance in the
child and the community.Page 7 of 9
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Our study shows that Aboriginal infants with OME receiv-
ing continuous amoxicillin had more normal ears, fewer
perforations and less pneumococcal carriage. There was
no statistically significant increase in resistant pneumo-
cocci or NCHi in amoxicillin children compared to pla-
cebo children who received regular paediatric care and
antibiotic treatment for symptomatic illnesses. The option
to use long-term antibiotics would be less relevant for
western populations where the outcome of untreated OM
is less severe, and the balance of benefit and risk is less
influenced by the risk of a severe clinical outcome, and
more influenced by the potential for increased antibiotic
resistance in the child and the community.
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